• US therapeutic: $611M (-6% QoQ, +4% YoY) • US cosmetic: $389M (-14% QoQ*, -5% YoY) -- US total: $1.00B (61% therapeutic; 39% cosmetic) was 72% of worldwide total
*Botulinum-toxin sales for cosmetic indications are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.